RxDoctor Payments Data

Andrew Quint, MD

Internal Medicine · Columbia, MONPI 1245238005

Payments from drug & device makers

$724in general payments, 2019–2025

Across 56 payments — averaging $12.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$240
  • Gilead$73
  • Dexcom, Inc.$56
  • Merck$54
  • GSK$52
  • Novo Nordisk$47
  • plus $202 from 9 others

What the payments were for

  • Food & beverage$68895%
  • Education$365%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$724 in reported general payments places this provider in the 65th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$1,180
Medicare patients
28
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin163$141,201
OzempicSemaglutide92$131,167
RybelsusSemaglutide66$68,608
EliquisApixaban81$59,163
TrulicityDulaglutide61$58,572
FarxigaDapagliflozin Propanediol59$46,847
Spiriva RespimatTiotropium Bromide64$36,927
Bydureon BciseExenatide Microspheres43$35,025
Tresiba Flextouch U-200Insulin Degludec29$34,303
OxycontinOxycodone Hcl49$33,850
LinzessLinaclotide56$29,862
Spiriva HandihalerTiotropium Bromide45$26,975
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$26,359
Advair HfaFluticasone Propion/Salmeterol44$22,019
Tresiba Flextouch U-100Insulin Degludec29$19,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$47$199,775158 claims
Lilly USA, LLCTrulicity, Mounjaro$39$75,77375 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$52$45,44485 claims
AbbVieLinzess$240$29,86256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →